Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

In a clinical trial, a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release ...

Extended-release buprenorphine was an effective treatment for pregnant women with opioid use disorder (OUD) and safe for their babies, according to an open-label randomized trial.

Between four and 10 million people in the U.S. have fibromyalgia. Many doctors look askance at the disorder, leading some ...

Diagnoses of opioid use disorder and opioid overdoses were rare in the 12 months following index visits (n = 2362; 0.3%). The Epic model showed low sensitivity to correctly identify people at risk ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, drinking and opioid use disorders and addiction.

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency ...

Buprenorphine was associated with a 50% reduction in mortality and improved treatment retention for adolescents with opioid use disorder.